In another study, Zhu et al. reported that despite the frequent amplification of RNF19A in cancer, RNF19A increases cell sensitivity to PARP inhibitors by inhibiting homologous recombination (HR)-mediated DNA damage repair [66]. Here, RNF19A is linked to cancer.